Revolution Medicines' Pancreatic Cancer Drug Daraxonrasib Shows Promising Results in Phase 3 Trial
Revolution Medicines has announced successful results from a Phase 3 trial of its pancreatic cancer drug, daraxonrasib. The trial demonstrated that the drug nearly doubled the typical length of survival for patients and reduced the risk of death by 60% compared to chemotherapy. Daraxonrasib targets RAS mutations, which are prevalent in pancreatic cancer cases. The company plans to seek FDA approval using a Commissioner's National Priority Voucher, which could expedite the review process. The drug's success in the trial marks a significant advancement in the treatment of pancreatic cancer, a disease known for its low survival rates. 
